0001193125-26-144470
SEC filingJaguar Health reported $11.5M in revenue and a $53.6M net loss for FY2025, reflecting continued investment in pipeline development amid commercial transitions; gross margin remained strong at 67.2%, but operating losses widened significantly and cash flow from operations was deeply negative.
Operating income was -$45.9M, and net income was -$53.6M, or -$22.97 per diluted share. These results reflect the Company’s ongoing investment in clinical development, regulatory advancement, and commercial infrastructure. Management states plainly that expenditures are expected to increase as the Company continues developing its pipeline and advancing products — a dynamic directly reflected in the scale of the operating loss. No specific R&D dollar amounts or growth rates are supported in the authoritative packet, so analysis remains anchored to this forward-looking commitment rather than unsupported quantitative comparisons.
Net cash used in operating activities was -$23.7M, and capital expenditures were nominal at $16,000, yielding free cash flow of -$23.7M. This persistent outflow underscores structural cash consumption ahead of commercial scale. Management emphasizes active monitoring of capital resources and notes both favorable and unfavorable developments may materially impact financial position. Critically, the Company acknowledges substantial doubt about its ability to continue as a going concern — a conclusion rooted in current liquidity constraints and anticipated funding needs, not speculative projections. The absence of quantified cash balances or restricted funds in the authoritative packet precludes restating those figures; instead, the narrative reflects management’s own qualitative assessment of liquidity risk and financing strategy.